Navigation Links
AGI Dermatics Data Shows the 8 Oxo-Guanine Repair Enzyme OGG1,Encapsulated in Liposomes, Reduces MMP-1 and TNF-alpha in UV,Irradiated Skin Cells

Clinical Data Presented at the Society for Investigative Dermatology

FREEPORT, N.Y., May 16, 2007 /PRNewswire-FirstCall/ -- AGI Dermatics today announced new clinical research that the 8-oxo-guanine DNA glycosylase (OGG1) encapsulated in liposomes enhances DNA repair and reduces MMP-1 and TNF-alpha in UV irradiated skin cells. The data was presented at the 68th Annual Meeting of the Society for Investigative Dermatology, May 9 - 12, in Los Angeles, CA.

"Our clinical study suggests that OGGI liposomes enhance DNA repair in skin cells," said Daniel Yarosh, PhD, President, AGI Dermatics. "This is particularly exciting when we consider that existing data shows that 8-oxo- guanine causes the most significant damage to mitochondrial DNA, which manifests as nearly all signs of premature aging."

The study examined the question of, if by damaging DNA with reactive oxygen species (ROS) would there be an increase of either/both matrix metalloproteinase-1 (MMP-1) and tumor necrosis factor, two factors known to play roles in photoaging. The formation of 8-oxo-G is induced by ROS from UVA irradiation, cigarette smoke, environmental stressors, endogenous enzymatic peroxidation reactions and normal mitochondrial metabolism. Those mentioned account for nearly all of the symptoms of premature skin aging. Long-term exposure consequences include photodamage, fine lines and wrinkles.

Natural cellular repair of the oxidative damage entails complete removal of 8-oxo-G from DNA via the enzyme OGGI. For the test, OOGI encapsulated in liposomes showed that the delivery of this enzyme into fibroblasts increases the rate of repair of 8-oxo-G, and reduces mitochondrial toxicity and analyzed mRNA content and protein secretion of MMP-1 and TNF-alpha, with real-time RT- PCR and ELISA.

Normal human dermal fibroblasts (NHDF) were irradiated with solar- stimulating (ss) UV (UVA340 bulb) to induce MMP-1. Following irra
'"/>




Page: 1 2

Related medicine technology :

1. AGI Dermatics Presents Comparative Data That Indicates OCTN-1 Skin Cells Have the Ability to Recognize, Transport and Utilize L-ergothioneine (EGT) As A Protector Against Oxidative Damage
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
4. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
5. MediGene Announces Cancer-Fighting Virus Shows Promise in Early Clinical Trial
6. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
7. Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
8. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
9. CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
10. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
11. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
Post Your Comments:
(Date:5/8/2008)...he Cancer Research Alliance, an,organization compr...asking,303 million Americans to exercise their pow...fforts this Mother,s Day through Father,s Day., T..." has two key goals:,to activate Americans everywh...g together to exercise their collective power over...
(Date:5/8/2008)...tential of asenapine in the treatment of ...HINGTON, May 8 /- Schering-...hat an overview of asenapine clinical trials,from ...ual Meeting of the,American Psychiatric Associatio...ies, involving patients with bipolar I disorder an...
(Date:5/8/2008)...ire-FirstCall/ -- Siemens Healthcare and,Laborator...today announced,that they have entered a non-exclu...co-develop new clinical diagnostic tests in the ar...oncology and diabetes. Under the,agreement, initia...hat,could make the biggest impact to patient care....
(Date:5/8/2008)...wire-FirstCall/ -- VION PHARMACEUTICALS,INC. (Nas...tigator-sponsored,Phase I/II clinical trial of its...in combination with cytarabine in elderly patients...mia (AML) and high-risk,myelodysplastic syndromes ...ction of Ellen K. Ritchie, M.D. at The Weill-Corne...
Breaking Medicine Technology:World Renowned Cancer Centers Implore Americans to Donate $1 to Make Change and Accelerate Cancer Research 2World Renowned Cancer Centers Implore Americans to Donate $1 to Make Change and Accelerate Cancer Research 3World Renowned Cancer Centers Implore Americans to Donate $1 to Make Change and Accelerate Cancer Research 4World Renowned Cancer Centers Implore Americans to Donate $1 to Make Change and Accelerate Cancer Research 5Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 2Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 3Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 4Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 5Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 6Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting 7Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests 2Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests 3Siemens and LabCorp Enter Agreement to Co-Develop New Clinical Diagnostic Tests 4Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Cytarabine 2Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Cytarabine 3RxElite Filling Critical Requirement for Strategic Partners in Asia Europe and Australia 3837 1RxElite Filling Critical Requirement for Strategic Partners in Asia Europe and Australia 3837 2Cogdell Spencer Inc Announces the Closing of the Marshall Erdman and Associates Merger 13970 1Cogdell Spencer Inc Announces the Closing of the Marshall Erdman and Associates Merger 13970 2Hospital Caregivers Unveil Billboards Calling for Improved Patient Care Quality Jobs at Community Medical Centers 13967 1Kaiser Permanente Team Builds Prosthetic Hands for Charity 13964 1Kaiser Permanente Team Builds Prosthetic Hands for Charity 13964 2
(Date:5/13/2008)... HARBIN, China, May 13 /Xinhua-PRNewswire-FirstCa...oard: CSKI), a manufacturer, marketer and,distribu...oducts in China,today announced that it will cond... May 15, 2008 to discuss its first quarter 2008 fi...man, CEO and Director of China Sky One,Medical, In...
(Date:5/13/2008)...ildbearing had no such benefit if baby was bottle-...13 (HealthDay News) -- Women who breast feed for m...arthritis (RA) by half, according to a new Swedish...g children but not breast-feeding offered women no...contraceptives also failed to reduce the risk of R...
(Date:5/13/2008)...NEW YORK (May 13, 2008) -- Promising results from ...ell Medical Center physician-scientists show that ... the progression of Batten disease, or Late Infant..., genetic, degenerative neurological disorder that... to 12. , The clinical trial found that the pro...
(Date:5/13/2008)... SALT LAKE CITY, May 13 /PRNewswire/ -- Paramed S...ent of their marine-grade Mobility Offers,Versatil...chair to oil and,gas platform operators in the Gul...platforms will enable the safe and timely evacuati...atform., Paramed developed the dual-track MOV in ...
Breaking Medicine News(10 mins):Health News:China Sky One Medical, Inc. Announces Conference Call to Discuss First Quarter 2008 Results 2Health News:Breast-feeding Might Shield Women From Rheumatoid Arthritis 2Health News:NYP/Weill Cornell gene therapy clinical trial yields promising results for Batten disease 2
... tortillas probably doesn't come to mind. But a Ka...with ways to add fiber to the foods we love witho.... Sajid Alavi is an assistant professor of grain ...ollege of Agriculture. His expertise is in extrusi...
...otting protein found in circulating blood, has bee...ystem neuronal cells , a process that is necessary...umatic injury. The findings by researchers at the...CSD) School of Medicine, may explain why the human...
...12 weeks pregnant with rocker boyfriend Joel Madde...fe" star, is reported to have shared the joyful ne...cluding Mischa Barton. However, she is neither co...r pregnancy to the media. Apart from her impendin...
...covered from the bottom of a two-kilometre thick i...s much warmer at some point during the last Ice Ag...e trees, plants and insects of a boreal forest est...,000 years old. Previously, the youngest evidence ...
Other Medicine News:Health News:Snack Foods Fortified With Fiber 2Health News:Fibrinogen may Inhibit Spinal Cord Regeneration 2
VG2 PLIF Allograft is comprised of two cortical planks of bone surrounding a cancellous center. The cortical planks provide strength for anterior column support. The cancellous bone provides a lattic
Williams Micro Discectomy Instruments are designed to be used in the microsurgical treatment of herniated disks.
Meyerding Laminectomy Retractors, self-retaining.
Karlin Crank Frame Spinal Retractor Set is designed for posterior lumbar and thoracic spine surgery. Arm design allows the blades be pre-positioned in the wound prior to attachment.
Medicine Products: